Analyst Price Targets — BMY
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| April 8, 2026 11:33 am | — | Cantor Fitzgerald | $54.00 | $59.20 | TheFly | Bristol Myers price target raised to $54 from $45 at Cantor Fitzgerald |
| March 6, 2026 12:44 pm | Michael Yee | UBS | $70.00 | $59.79 | StreetInsider | Bristol-Myers Squibb Co. (BMY) PT Raised to $70 at UBS Ahead of Major Catalyst |
| February 24, 2026 9:03 pm | Trung Huynh | RBC Capital | $60.00 | $61.60 | StreetInsider | RBC Capital Starts Bristol-Myers Squibb Co. (BMY) at Sector Perform |
| February 23, 2026 11:32 am | — | Piper Sandler | $75.00 | $60.66 | TheFly | Bristol Myers price target raised to $75 from $66 at Piper Sandler |
| February 19, 2026 9:15 pm | — | Barclays | $75.00 | $60.30 | TheFly | Bristol Myers initiated with an Overweight at Barclays |
| February 6, 2026 3:41 pm | Terence Flynn | Morgan Stanley | $40.00 | $61.86 | TheFly | Bristol Myers price target raised to $40 from $37 at Morgan Stanley |
| February 6, 2026 12:22 pm | — | Guggenheim | $72.00 | $59.52 | TheFly | Bristol Myers price target raised to $72 from $62 at Guggenheim |
| February 6, 2026 11:21 am | Mohit Bansal | Wells Fargo | $60.00 | $59.52 | TheFly | Bristol Myers price target raised to $60 from $55 at Wells Fargo |
| January 28, 2026 11:42 am | — | Piper Sandler | $66.00 | $55.56 | TheFly | Bristol Myers price target raised to $66 from $62 at Piper Sandler |
| January 13, 2026 2:13 pm | David Risinger | Leerink Partners | $60.00 | $56.39 | TheFly | Bristol Myers price target raised to $60 from $54 at Leerink |
Latest News for BMY
BOSTON--(BUSINESS WIRE)--Foundation Medicine, Inc., a global precision medicine company, today announced an expansion to its collaboration with Bristol Myers Squibb (NYSE: BMY) to develop FoundationOne®CDx as a next-generation sequencing-based companion diagnostic to identify patients with homozygous MTAP deletion in multiple indications for an investigational targeted therapy. The expansion broadens Foundation…
BMY pivots to growth portfolio as legacy drugs decline, with rising new therapies helping offset revenue erosion and reshape the long-term outlook.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Bristol-Myers Squibb (NYSE:BMY | BMY Price Prediction) trades at $60.17 as of writing.
WALTHAM, Mass., April 20, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs, today announced the appointment of Felecia W.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
Senate Trading Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.